Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Capital Expenditures (2020 - 2023)

BioAtla's Capital Expenditures history spans 4 years, with the latest figure at $8000.0 for Q4 2023.

  • For Q4 2023, Capital Expenditures changed N/A year-over-year to $8000.0; the TTM value through Sep 2024 reached $8000.0, down 91.11%, while the annual FY2023 figure was $98000.0, 9700.0% up from the prior year.
  • Capital Expenditures reached $8000.0 in Q4 2023 per BCAB's latest filing, down from $25000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $916000.0 in Q4 2021 to a low of -$86000.0 in Q3 2020.
  • Average Capital Expenditures over 4 years is $107533.3, with a median of $15000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: crashed 86.49% in 2022, then skyrocketed 400.0% in 2023.
  • A 4-year view of Capital Expenditures shows it stood at $590000.0 in 2020, then surged by 55.25% to $916000.0 in 2021, then crashed by 103.49% to -$32000.0 in 2022, then surged by 125.0% to $8000.0 in 2023.
  • Per Business Quant, the three most recent readings for BCAB's Capital Expenditures are $8000.0 (Q4 2023), $25000.0 (Q3 2023), and $15000.0 (Q2 2023).